Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104142 | 0.95 | MAOA (0.42) | MAOAMAOBCNR1SMN1; SMN2MAT2A | |
| SCHEMBL4109181 | 0.90 | ALDH1A1 (0.36) | MAOAMAOBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4099332 | 0.88 | CNR1 (0.41) | MAOAMAOBCNR1SMN1; SMN2HIF1A | |
| SCHEMBL4093348 | 0.87 | CTSS (0.39) | MAOAMAOBCTSS | |
| SCHEMBL4099269 | 0.86 | CNR1 (0.48) | MAOAMAOBCNR1SMN1; SMN2HIF1A | |
| SCHEMBL4104374 | 0.85 | ALDH1A1 (0.35) | MAOAMAOBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4107328 | 0.84 | MAOB (0.40) | MAOAMAOBCNR1SMN1; SMN2HIF1A | |
| SCHEMBL4525318 | 0.83 | CNR1 (0.38) | MAOAMAOBCNR1MAT2ALMNA | |
| SCHEMBL4517383 | 0.81 | CNR1 (0.37) | MAOAMAOBCNR1MAT2ALMNA | |
| SCHEMBL4099250 | 0.80 | MCHR1 (0.40) | MAOAMAOBCNR1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | claimed |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | MAOA 3635/4885MAOB 3390/4885CNR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.